Farnesyl transferase inhib 
Welcome,         Profile    Billing    Logout  
 4 Companies  4 Products   4 Products   269 Diseases   19 Trials   977 News 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zarnestra (tipifarnib) / Kura Oncology
2004-001719-77: A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or older.

 
3
21
Europe
Zarnestra 100mg Tablets, R115777,
Johnson & Johnson Pharmaceutical Research and Development, Johnson&Johnson Pharmaceutical Research and Development, Janssen-Cilag International NV, Janssen-Cilag Limited, Johnson&Johnson Pharmaceutical Research and Development, Division de Janssen-Cilag, JANSSEN-CILAG, Janssen-Cilag International N.V.
Treatment of Acute Myeloid Leukemia (AML)
 
10/07
2005-002847-14: AML16; A National Cancer Research Institute Trial in Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndromes

Ongoing
2/3
2000
Europe
Clofarabine, Mylotarg, Azacitidine, Zarnestra, Clofarabine, Gemtuzumab Ozogamicin, Azacitidine, Zarnestra, Clofarabine, Mylotarg, Vidaza, Clofarabine, Mylotarg, Vidaza
Cardiff University
Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome
 
 
NCT00021203: R115777 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Active, not recruiting
2
US
chemotherapy, tipifarnib
H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI)
Multiple Myeloma and Plasma Cell Neoplasm
 
 
NCT00060177: Letrozole With or Without Tipifarnib in Treating Women With Locally Advanced, Locally Recurrent, or Metastatic Breast Cancer

Active, not recruiting
2
US
letrozole, tipifarnib
University Hospitals Seidman Cancer Center, National Cancer Institute (NCI)
Breast Cancer
 
 
NCT00678951: Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults

Recruiting
2
90
US
PEG-interferon alfa-2b, MRI
National Cancer Institute (NCI)
Neurofibromatosis Type 1, Plexiform Neurofibroma
01/16
01/16
2017-004822-13: A research study to evaluate the response rate of tipifarnib in patients with locally advanced unresectable or metastasic, relapsed and/or refractory, squamous non-small cell lung cancer with HRAS mutations Un estudio de investigación para evaluar la tasa de respuesta de tipifarnib en pacientes con cáncer de pulmón no microcítico escamoso localmente avanzado irresecable o metastásico, recidivante y/o refractario al tratamiento con mutaciones de HRAS

Not yet recruiting
2
18
Europe
Tipifarnib, R115777, Film-coated tablet
Spanish Lung Cancer Group (SLCG/GECP), Spanish Lung Cancer Group (SLCG/GECP)
squamous non-small cell lung cancer (SQ-NSCLC) Pacientes con cáncer de pulmón no microcítico escamoso localmente avanzado irresecable o metastásico, Squamous non small cell lung cancer harbouring HRAS mutation Pacientes con cancer de pulmon no microcitico escamoso con mutación HRAS, Diseases [C] - Cancer [C04]
 
 
NCT02535650: Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma

Active, not recruiting
2
19
RoW
tipifarnib
Samsung Medical Center
Urothelial Carcinoma
03/22
06/22
NCT03496766: Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

Terminated
2
9
Europe
Tipifarnib, Zarnestra
Spanish Lung Cancer Group
Non Small Cell Lung Cancer
10/22
11/22
SEQ-HN, NCT03719690 / 2018-001437-40: Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

Completed
2
296
Europe, US, RoW
Tipifarnib, HRAS Detection Assay
Kura Oncology, Inc.
HRAS Gene Mutation, HNSCC
05/23
05/23
NCT06540963: Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Not yet recruiting
2
98
US
Tipifarnib, R115777, Naxitamab, Danyelza
Giselle Sholler
Neuroblastoma Recurrent
08/30
08/35
MATCH, NCT03155620: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric Screening Trial)

Recruiting
2
2316
Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ensartinib, Ensacove, X 396, X-396, X396, Erdafitinib, Balversa, JNJ 42756493, JNJ-42756493, JNJ42756493, Laboratory Biomarker Analysis, Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mutation Carrier Screening, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, PD0332991, Pharmacological Study, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Samotolisib, 2H-Imidazo(4,5-C)quinolin-2-one, 1,3-Dihydro-8-(5-(1-hydroxy-1-methylethyl)-3-pyridinyl)-1-((2S)-2-methoxypropyl)-3-methyl-, LY 3023414, LY-3023414, LY3023414, WHO 10889, Selpercatinib, LOXO 292, LOXO-292, LOXO292, RET Kinase Inhibitor LOXO-292, Retevmo, Retsevmo, WHO 10967, Selumetinib Sulfate, AZD-6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulphate, Koselugo, Selumetinib Sulphate, Tazemetostat, E 7438, E-7438, E7438, EPZ 6438, EPZ-6438, EPZ6438, Tipifarnib, R115777, Zarnestra, Ulixertinib, BVD-523, VRT752271, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX 4032, PLX-4032, PLX4032, RG 7204, RG-7204, RG7204, RO 5185426, RO-5185426, Zelboraf, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
09/27
09/27
NCT04284774: Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Active, not recruiting
2
5
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Tipifarnib, R115777, Zarnestra
National Cancer Institute (NCI)
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
03/24
04/25
NCT00005846: Tipifarnib in Treating Patients With Myeloproliferative Disorders

Active, not recruiting
1/2
US
tipifarnib
Stanford University, National Cancer Institute (NCI)
Leukemia, Myelodysplastic/Myeloproliferative Neoplasms
 
 
KURRENT-HN, NCT04997902: Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Recruiting
1/2
40
US
Tipifarnib, Alpelisib, BYL719
Kura Oncology, Inc.
HNSCC
09/24
09/24
NCT04865159: Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies

Terminated
1
6
US
Tipifarnib
Kura Oncology, Inc.
Advanced Solid Tumor
05/23
05/23
NCT05693090: Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Withdrawn
1
50
US
Tipifarnib, Osimertinib
Kura Oncology, Inc.
NSCLC
07/27
07/27
NCT04809233: Expanded Access to Tipifarnib

Available
N/A
NA
Tipifarnib
Kura Oncology, Inc.
HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
 
 
Zokinvy (lonafarnib) / Eiger
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
LOWR6, NCT05229991: Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection

Active, not recruiting
3
30
RoW
Lonafarnib, LNF, Ritonavir, Norvir
Soroka University Medical Center, Eiger BioPharmaceuticals
Hepatitis D, Chronic
12/24
04/25
NCT02960360: A Phase 2b Study of Lonafarnib With or Without Ritonavir in Patients With HDV

Not yet recruiting
2b
60
US, RoW
Lonafarnib, EBP994, Sarasar, Ritonavir, Norvir
Eiger BioPharmaceuticals
Chronic Delta Hepatitis
12/18
 
NCT00916747: Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

Active, not recruiting
2
85
US
Lonafarnib, Zoledronic Acid, and Pravastatin
Boston Children's Hospital, Schering-Plough, Merck Sharp & Dohme LLC, Eiger BioPharmaceuticals
Progeria
02/22
12/23
NCT05953545: Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis

Withdrawn
2
30
US
Peginterferon Lambda
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis Delta
05/24
05/24
NCT02579044: Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria

Enrolling by invitation
1/2
80
US
Everolimus and lonafarnib
Boston Children's Hospital
Progeria
12/23
12/23
NCT00102648: Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

Active, not recruiting
1
34
US
Lonafarnib, 4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, Sarasar, SCH 66336, SCH-66336, SCH66336, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma
03/25
12/25
ChiCTR2100050052: Observational study of Lonafarnib in Chinese patients with progeria and progeroid laminopathy

Not yet recruiting
N/A
25
 
Treatment with Lonafarnib
The Children's Hospital Zhejiang University School of Medicine; The Children's Hospital Zhejiang University School of Medicine, self-funded
Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies
 
 
KO-2806 / Kura Oncology
FIT-001, NCT06026410: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Recruiting
1
270
US
KO-2806, Cabozantinib, Cabometyx, Adagrasib, Krazati
Kura Oncology, Inc., Mirati Therapeutics Inc.
Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC)
01/27
04/27
LNK-754 / AstraZeneca
No trials found

Download Options